Tamsulon Duo

Quick links

Choose a section

Quick links to important sections

Advertisements

Tamsulon Duo

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Tamsulon Duo

Quick Facts

Property Description
Active ingredients Dutasteride, Tamsulosin
Form Oral hard capsule
Pharmacological class 5α-reductase inhibitor + α₁-blocker
Common use Management of Benign Prostatic Hyperplasia (BPH)
Origin Synthetic

What Type of Medicine is Tamsulon Duo?

Tamsulon Duo is a synthetic, prescription-only pharmaceutical preparation and a dual-acting urological agent for the management of prostate-related conditions. This medication is administered as a single oral hard capsule, specifically designed as a fixed-dose combination (FDC) product. The FDC structure ensures that two distinct and synergistic drug mechanisms are delivered simultaneously in one unit for therapeutic compliance.

Dutasteride and Tamsulosin: A Dual-Action Composition

The composition of Tamsulon Duo is defined by its two active compounds: Dutasteride and Tamsulosin (used as Tamsulosin hydrochloride). These ingredients belong to two non-overlapping pharmacological classes: Dutasteride is classified as a 5α-reductase inhibitor (5-ARI), and Tamsulosin is an alpha-1 adrenergic receptor antagonist (α₁-blocker). The combination is indicated for adult male patients with an enlarged prostate, offering a dual-mechanism strategy compared to using either agent alone.

General Purpose and Synergistic Benefit

The general therapeutic purpose is the long-term management of Benign Prostatic Hyperplasia (BPH). The dual composition provides a synergistic effect: the Tamsulosin component provides smooth muscle relaxation in the urinary tract, which helps improve the flow of urine. Concurrently, the Dutasteride component facilitates the reduction of the prostate gland size over time by inhibiting hormonal factors.

Advertisements

What side effects are possible with Tamsulon Duo?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety constraints for Tamsulon Duo (dutasteride/tamsulosin) as documented in official regulatory sources. This information is strictly descriptive and non-advisory.

Frequency-Classified Adverse Reactions

The following are classified based on the frequency observed in clinical trials:

  • Common (1 in 100 to 1 in 10 patients): Dizziness, impotence, decreased libido, ejaculation disorders, and breast disorders (including enlargement and tenderness).
  • Uncommon (1 in 1,000 to 1 in 100 patients): Headache, palpitations, orthostatic hypotension (a drop in blood pressure upon standing), rhinitis, constipation, diarrhea, nausea, vomiting, urticaria, rash, itching, and asthenia (weakness).
  • Rare (1 in 10,000 to 1 in 1,000 patients): Syncope (fainting) and angioedema (swelling of the face, tongue, or throat).
  • Very Rare (Fewer than 1 in 10,000 patients): Stevens-Johnson syndrome (a severe skin reaction) and priapism (a persistent, painful erection).

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions documented include severe allergic reactions (angioedema, Stevens-Johnson syndrome) and priapism, which require immediate medical attention. The label also documents observations of a higher incidence of high-grade prostate cancer (Gleason 8–10) in some studies involving the dutasteride component.

Population-Specific Safety: The medicine is contraindicated for use in women and children. Due to the risk of harm to a male fetus, pregnant women must not handle leaking capsules. Men taking this medicine should not donate blood and must use a barrier contraceptive during treatment and for six months after the last dose.

Procedural Constraints: Prior use of the tamsulosin component is a risk factor for Intraoperative Floppy Iris Syndrome (IFIS), a complication during cataract or glaucoma surgery. The eye surgeon must be informed of the patient's history with the medication.

Advertisements

Overdose and Emergency Response

Overdose with Tamsulon Duo is clinically defined by the effects of its Tamsulosin component, primarily presenting as significant hypotension (low blood pressure). Documented symptoms may include pronounced dizziness, syncope (fainting), blurred vision, or headache. A severe or suspected overdose requires immediate medical attention. Patients or caregivers must contact a poison control center or call emergency services right away, particularly if the individual collapses, has a seizure, or experiences difficulty breathing. The regulatory guidance specifies that the occurrence of Priapism (a painful erection lasting longer than four hours) is also an urgent medical emergency.

Overdose management is strictly symptomatic and supportive. Because there is no specific antidote known for the Dutasteride component, treatment focuses on stabilizing the patient’s condition. Procedures to restore normal circulation include having the patient lie down, the administration of volume expanders (fluids), and potentially the use of vasopressors to elevate blood pressure. Hospital monitoring is required for observation of cardiovascular stability.

Advertisements

Therapeutic Uses of Tamsulon Duo

Quick Facts

  • Primary Use: Management of symptoms associated with benign prostatic hyperplasia (BPH).
  • Target Symptoms: May help ease difficulties with urination, a weak stream, and increased frequency or urgency of urination.
  • Clinical Goal: To improve urine flow and contribute to long-term patient well-being.

Tamsulon Duo is a fixed-dose combination medication used for the symptomatic treatment of benign prostatic hyperplasia (BPH) in men. BPH, also known as an enlarged prostate, is a condition that can result in lower urinary tract symptoms (LUTS) as men age.

The medication is indicated for use in men with moderate-to-severe BPH symptoms to assist with managing discomfort and difficulties related to urination. It may help improve the flow of urine and may contribute to reducing certain risks associated with BPH progression, such as acute urinary retention or the potential need for surgical intervention in some cases. The goal of using this treatment is to help alleviate the bothersome symptoms of BPH and support long-term patient well-being.

This option is generally prescribed after a healthcare provider has evaluated the patient’s condition and determined that dual therapy is appropriate for symptom control.

Regulatory References

  1. NIH MedlinePlus guidance on the combination therapy
Advertisements

Eligibility and Restrictions for Use

Tamsulon Duo is officially indicated only for adult males with symptomatic benign prostatic hyperplasia (BPH) and is subject to strict eligibility rules based on regulatory classification.

Contraindicated Populations and Conditions

This medicine is contraindicated in several groups. It must not be used by women under any circumstances, including women who are pregnant or may become pregnant, due to the serious risk of fetal harm to a male fetus from the dutasteride component. It is also contraindicated for all individuals under 18 years of age (pediatric population). Absolute non-eligibility applies to patients with a history of orthostatic hypotension, known severe hepatic impairment (severe liver disease), or a documented hypersensitivity to any component.

Restricted or Conditional Use

Use is restricted or requires caution in other specific populations. Patients with severe renal impairment (creatinine clearance <10 mL/min) have limited or absent clinical data, and use should be approached carefully. Furthermore, men with a pregnant partner must use a barrier form of contraception to avoid semen exposure. The initiation of therapy is not recommended for patients scheduled for cataract or glaucoma surgery due to the risk of Intraoperative Floppy Iris Syndrome (IFIS).

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interaction profile for Tamsulon Duo (Dutasteride/Tamsulosin) based strictly on regulatory sources, focusing on pharmacokinetic and pharmacodynamic patterns.

Contraindicated Combinations

Co-administration with strong CYP3A4 inhibitors, such as ketoconazole, is formally contraindicated. These agents significantly decrease the clearance of Tamsulosin, leading to a marked increase in plasma exposure. The fixed-dose combination is also contraindicated with other alpha-adrenergic blocking agents (e.g., alfuzosin, doxazosin) due to the documented risk of additive symptomatic hypotension.

Documented Pharmacokinetic and Pharmacodynamic Interactions

The Tamsulosin component is metabolized by both CYP3A4 and CYP2D6. Strong inhibitors of CYP2D6, such as paroxetine, require caution as they increase Tamsulosin exposure. Furthermore, co-administration with Phosphodiesterase Type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) requires caution due to a pharmacodynamic interaction that raises the potential for hypotension. Agents like Diclofenac and Warfarin may alter the Tamsulosin elimination rate.

Other Interaction Constraints

Specific administration-timing rules apply to ensure consistent absorption: the medication must be taken approximately 30 minutes after the same meal each day. The combination is also contraindicated in patients with severe hepatic impairment. Alcohol ingestion may increase the risk of hypotensive effects.

Advertisements

Mechanism of Action

The action of this drug is achieved through two distinct and complementary mechanistic pathways that influence structural and functional elements of the lower urinary tract. The combined mechanisms result in both a long-term structural modulation and an immediate functional modulation of the target tissues.

Targeted Blockade of Smooth Muscle Tension

This component works by acting as an antagonist (blocker) on alpha1A-adrenergic receptors found in the smooth muscle of the lower urinary tract. By preventing the binding of the sympathetic neurotransmitter norepinephrine to these receptors, the drug immediately reduces the dynamic tension within the prostatic capsule and bladder neck. This physiological change results in a reduction in dynamic resistance against fluid outflow.

Sustained Reduction of Androgen-Driven Tissue Mass

The second mechanistic domain involves the irreversible inhibition of the 5alpha-reductase enzyme (Type 1 and Type 2), which is responsible for converting testosterone into the highly potent Dihydrotestosterone (DHT). The resulting prolonged reduction in intraprostatic DHT levels gradually decreases the hormonal drive for cellular proliferation, leading to a long-term decrease in the physical volume and mass of the prostatic tissue.

Advertisements

Dosage and Administration Information

The Dutasteride/Tamsulosin fixed-dose combination is administered via the oral route as a hard capsule. The medicine contains a fixed dose of 0.5 mg Dutasteride and 0.4 mg Tamsulosin Hydrochloride. The standard adult regimen is one capsule taken once daily. This regimen is intended for continuous, long-term administration.

Proper administration requires adherence to a specific time constraint: the capsule must be taken approximately 30 minutes after the same meal each day to ensure consistent use and absorption. A critical procedural condition is the integrity of the capsule: the medicine must be swallowed whole and must not be chewed, opened, or crushed. Altering the capsule can cause local irritation to the oropharyngeal mucosa.

If a dose is missed, the procedure is to skip the missed dose and resume the schedule with the next dose at the regular time; missed doses should never be doubled.

Regarding specific populations, no dosage adjustment is necessary for older adults or for patients with mild-to-severe renal impairment. However, the combination is contraindicated in cases of severe hepatic impairment, underscoring a key usage constraint for patients with severe liver conditions.

Advertisements

Recent Clinical Evidence

Research Evidence for Tamsulon Duo


Evidence for LUTS Studies in BPH

Research for Tamsulon Duo utilizes large-scale Randomized Controlled Trials (RCTs) and subsequent analyses. These studies primarily included adult male patients diagnosed with Benign Prostatic Hyperplasia (BPH) who were experiencing moderate-to-severe Lower Urinary Tract Symptoms (LUTS), a condition where symptoms may vary in intensity.

Research examined how symptoms changed over time in these study populations. The key outcomes monitored included symptom measurements, such as the International Prostate Symptom Score (IPSS), and functional changes, such as the Maximum Urinary Flow Rate ( Q max). Findings describe patterns observed in the studies regarding the evolution of both symptom scores and urine flow rates when comparing the combination to its individual components. However, results apply only to the populations studied, which were largely defined by specific criteria for prostate size and symptom severity.

Evidence for BPH Progression Studies

Beyond short-term symptom investigation, Tamsulon Duo was studied for its role in long-term disease progression research. This research was structured around long-term Randomized Controlled Trials specifically designed to observe the time until a major BPH-related event occurred. These studies focused on adult male patients identified as having an elevated risk of progression.

Research examined outcomes related to systemic or functional imbalance by measuring the time until patients experienced a composite endpoint, such as Acute Urinary Retention (AUR) or the need for BPH-related surgery. Data show patterns related to the incidence of these progression events over the full 4-year follow-up duration of the core trials. The evidence base for these long-term events reflects the design of pivotal RCTs, which were specifically intended to measure these long-term clinical patterns.

Research Gaps and What Remains Uncertain

A number of research gaps and limitations have been identified. Firstly, long-term effects are not fully established beyond the four-year study periods. Evidence is limited for certain subgroups, such as patients with significant comorbidities or those with impaired liver function (hepatic impairment).

Additionally, a structural limitation noted in the research is that the core progression trial did not include a fully placebo-controlled arm for the full study duration. It is important to remember that study results findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patterns observed in the clinical trials.

Key Studies & References

  1. Study Details | NCT00090103 | Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment (CombAT Study)
  2. NICE guideline on lower urinary tract symptoms in men (CG97) - Section on combination therapy
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tamsulon Duo (FAQ)

Q: How quickly can a patient expect to see a general improvement in urinary flow?

The functional component of the medicine is designed to act rapidly. Official reports indicate that flow symptoms may begin to improve within one week. However, reports suggest the full functional effects may be observed over two to four weeks.


Q: Does the full effect of Tamsulon Duo happen right away or over an extended period?

The maximum observed benefit in studies is generally achieved over a long period. Official product information indicates that because the Dutasteride component works gradually to reduce prostate size, the maximum observed benefit in clinical reports is generally seen after six months or more of continuous use.


Q: Has Tamsulon Duo been linked to reported vision changes or eye problems?

Vision problems are generally not described as a common side effect of this medicine. However, the Tamsulosin component has been associated with a complication during cataract or glaucoma surgery called Intraoperative Floppy Iris Syndrome (IFIS). Regulatory information indicates the eye surgeon should be informed of the patient's history with this medicine before surgery.


Q: What signs are associated with a serious, but rare, allergic reaction like angioedema?

Regulatory documents describe angioedema as a rare but serious allergic reaction. Signs of this reaction may involve swelling of the face, tongue, lips, or throat. The potential symptoms described include difficulty breathing or swallowing.


Q: Why must individuals taking Tamsulon Duo avoid blood donation for a certain period of time?

Regulatory guidelines state that individuals taking this medicine should not donate blood until at least six months have passed since their last dose. This measure is in place to prevent the Dutasteride component from being transferred, due to concerns regarding a male fetus.


Q: What is retrograde ejaculation, and is it a known potential effect of Tamsulon Duo?

Ejaculation disorders are a common side effect associated with the Tamsulosin component. Regulatory information describes retrograde ejaculation—a condition where semen goes into the bladder instead of leaving the body—as a specific type of this reported effect.


Q: Are there reports of persistent sexual side effects after stopping Tamsulon Duo?

In clinical observations, sexual side effects generally resolve after discontinuation. However, some regulatory reports mention rare, isolated cases of sexual dysfunction, such as low libido or difficulty with erection, that were reported to continue after discontinuation of the Dutasteride component.


Q: Does the consumption of grapefruit juice or products affect how the medicine works?

Official prescribing information indicates that caution or avoidance of grapefruit juice and grapefruit-containing products may be necessary. Grapefruit can affect the way the body processes the Tamsulosin component, potentially increasing the drug’s concentration and raising the risk of side effects like dizziness.


Q: Are there specific antibiotics or antifungals that should be used cautiously with Tamsulon Duo?

Regulatory documents identify certain classes of antibiotics and antifungals that have a potential for interaction with this medicine. Agents like certain antifungals (such as ketoconazole) and antibiotics (such as erythromycin) are known to affect drug metabolism and are either contraindicated or should be used with caution due to increased exposure to the Tamsulosin component.


Q: Does Tamsulon Duo have known interactions with over-the-counter supplements or herbal products?

General government warnings advise patient caution when using any over-the-counter or herbal product with prescription medication. Additionally, some official drug labels specifically reference avoiding certain herbal medicines. For example, products like St. John's Wort are mentioned because they may affect the metabolism or concentration of the drug components.


Q: How does taking Tamsulon Duo affect the results of a PSA blood test?

The Dutasteride component is known to affect the results of the PSA blood test, which is used to monitor prostate health. Official data indicates that the medicine reduces the PSA concentration by approximately 50% after several months of use. It is noted that healthcare providers should account for this reduction when interpreting test results.


Q: What is the general information about discontinuing Tamsulon Duo and the return of symptoms?

Available studies suggest that prostate tissue may regrow when the Dutasteride component is stopped. This prostate regrowth has been associated with a deterioration of lower urinary tract symptoms (LUTS). The data suggests that this potential change may necessitate further medical management.

Advertisements

How should Tamsulon Duo be stored and disposed of?

Storage and Disposal of Dutasteride and Tamsulosin Hydrochloride Capsules

The medicine must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container, tightly closed, and stored away from excess heat, moisture, and freezing conditions. All medicine must be kept out of the sight and reach of children.

Handling and Waste

Females who are pregnant or who may become pregnant must not handle the capsules due to the risk of exposure to the Dutasteride component. Any unused or expired medicine must not be thrown away via household waste or wastewater. Individuals must consult a pharmacist or local authority for the proper method of disposal, adhering to regulated pharmaceutical waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tamsulon Duo found in:

A-Z Index: